|
|
||||||||
Ann Thorac Surg 2004;78:1812-1813
© 2004 The Society of Thoracic Surgeons
Division of Cardiac Surgery, Toronto General Hospital, EN 14-215, 200 Elizabeth St, Toronto, Ontario M5G-2C4, Canada
| The first 20% of the full text of this article appears below. |
Pompilio and colleagues report on the mobilization, harvesting, and purification of AC133+ cells followed by myocardial implantation at the time of coronary artery bypass grafting (CABG). Cell therapy offers the promise to regenerate the heart after a myocardial infarction. Skeletal myoblasts were the first cell type to be transplanted at the time of CABG into regions that could not be revascularized to assess safety and possible efficacy [1]. This phase I trial was well controlled.
Recent studies demonstrated that bone marrow cells [2, 3] contributed to
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |